Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of trametinib in preparation of anti-arenavirus antiviral preparation

An arenavirus and antiviral technology, which is applied in the directions of antiviral agents, medical preparations containing active ingredients, pharmaceutical formulations, etc., can solve the problems of not obtaining approval for specific inhibition of arenaviruses, etc., and achieve a good therapeutic effect.

Active Publication Date: 2021-06-15
WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] There are currently no approved drugs that specifically inhibit arenaviruses

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of trametinib in preparation of anti-arenavirus antiviral preparation
  • Application of trametinib in preparation of anti-arenavirus antiviral preparation
  • Application of trametinib in preparation of anti-arenavirus antiviral preparation

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0038] Experimental example 1 inhibits the infection effect of multiple arenavirus pseudoviruses

[0039] Operation method:

[0040] 1) In the experiment, Vero E6 cells and A549 cells were cultured in DMEM medium containing 10% fetal bovine serum, and the cells were digested the day before the experiment, and the cells were inoculated to 96 cells at a cell density of 250,000 cells / mL. in the orifice plate.

[0041] 2) Trametinib was diluted with 2% DMEM medium on the day of the experiment, and the concentrations of LASV, LUJV and VSV were: 75 μM, 15 μM, 3 μM, 0.6 μM, 0.12 μM, 0.024 μM. The concentrations used for LCMV, JUNV, GTOV, MACV, SBAV and CHAPV are: 100 μM, 50 μM, 25 μM, 12.5 μM, 6.25 μM, 3.125 μM, 1.5625 μM, 0.78125 μM, 0.390625 μM, and then transfer 30 μl trametinib To the cell wells, the drug was incubated with the cells for 1 h.

[0042] 3) Dilute the virus after 1 hour. Place 20 µL of the virus dilution into the cell wells. Virus infection 1h. The virus is a ...

experiment example 2

[0049] Experimental example 2 inhibits the infection effect of LUJV-GPC recombinant virus

[0050] Operation method:

[0051] 1) In the experiment, Vero E6 cells and A549 cells were cultured in DMEM medium containing 10% fetal bovine serum, and the cells were digested the day before the experiment, and the cells were seeded into 96-well plates at a cell density of 250,000 cells / ml .

[0052] 2) On the day of the experiment, trametinib was diluted in DMEM medium with 2% fetal bovine serum to use concentrations: 75 μM, 15 μM, 3 μM, 0.6 μM, 0.12 μM, 0.024 μM. Afterwards, 30 μL of the drug was transferred to the cell well, and the drug was incubated with the cells for 1 h.

[0053] 3) After 1 hour, the virus was diluted at an MOI=0.1. Place 20 µL of the virus dilution into the cell wells. Virus infection 1h.

[0054] 4) The 96-well plate was replaced with 2% fetal bovine serum DMEM containing corresponding concentration of drugs for culture.

[0055] 5) After 24 hours, the d...

experiment example 3

[0057] Experimental Example 3: Inhibition of LCMV virus infection effect

[0058] Operation method:

[0059] 1) In the experiment, Vero E6 cells were cultured in DMEM medium containing 10% fetal bovine serum, and the cells were digested and inoculated one day before the experiment.

[0060] 2) Dilute the cells at a density of 250000 cells / mL, and inoculate 500 μL per well into a 24-well plate.

[0061] 3) On the day of the experiment, 200 μL of trametinib at different dilution concentrations was used to incubate the cells for 1 h. The diluted concentrations of trametinib were 75 μM, 15 μM, 3 μM, 0.6 μM, 0.12 μM, and 0.024 μM, respectively.

[0062] 4) After incubation for 1 hour, the cells were infected at MOI=0.1, and the original medium was aspirated after the cells were infected for 1 hour, and replaced with the medium containing the drug.

[0063] 5) Cells were lysed with TRIzol lysate 24 hours after infection, and samples were collected. After the samples were collect...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of trametinib in preparation of an anti-arenavirus antiviral preparation, and belongs to the technical field of medicine application. The invention particularly relates to application of trametinib in preparation of an antiviral preparation for inhibiting or killing arenavirus. The new application of trametinib is provided, the application range of trametinib is expanded, and particularly, trametinib can be used for preparing the antiviral preparation of the arenavirus and killing or inhibiting the arenavirus, and then can be used for treating arenavirus infection and diseases caused by the arenavirus infection.

Description

technical field [0001] The invention relates to the technical field of drug application, in particular to the application of trametinib in the preparation of antiviral preparations against arenaviruses. Background technique [0002] Mammalian arenaviruses belong to the Arenaviridae family of the order Bunyavirales. According to antigenicity, serology, geography and gene homology, mammalian arenaviruses are divided into two categories: old world arenaviruses and new world arenaviruses. [0003] Among the old world arenaviruses, there are two viruses that can cause hemorrhagic fever disease, namely Lassa virus (LASV) and Lujo virus (Lujo virus, LUJV). LASV causes Lassa hemorrhagic fever, which is endemic in West Africa. According to the World Health Organization, about 100,000 to 300,000 people are infected with Lassa fever each year, and about 5,000 people die. Infection with LUJV causes Lujo haemorrhagic fever, which was first identified in South Africa. LASV and LUJV ar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/519A61P31/14
CPCA61K31/519A61P31/14
Inventor 王薇刘洋曹浚垣肖庚富周旻旻郭娇
Owner WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com